Nature Medicine
Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Randomised trial in 284 peopleType 2 diabetes
Papers by Xianghua Zhang
5 results
- Signal Transduction and Targeted Therapy
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
Randomised trial in 250 peopleObesity - ADA Scientific Sessions 2026 Abstract
Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study
Trial in peopleInterventions - ADA Scientific Sessions 2025 Abstract
Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity
Trial in peopleInterventions
- ADA Scientific Sessions 2025 Abstract
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
Trial in peopleInterventions